Please join us in congratulating Ruby on the successful completion of Phase III BSL4 training. We're excited to share that she is now moving on to Phase IV - an impressive accomplishment.
Please join us in congratulating Dr. Ye on achieving Phase 4 full independence and clearance for unescorted access to the BSL-4 following successful completion of all required assessments.
Salarius Pharmaceuticals - through its subsidiary Decoy Therapeutics - is teaming up with the Martinez-Sobrido Lab at Texas Biomed to test novel peptide-conjugate fusion inhibitors across multiple...
Congratulations to Dr. Luis Martinez-Sobrido and his lab on earning two Faculty Oscars: Most Significant Contract Award for arenavirus research and Most Collaborative Faculty. These honors highlight...
Members of the Martinez-Sobrido Lab attended the recent Vaccine Development Center of San Antonio (VDCoSA) conference, where they presented their latest research and connected with colleagues across...
The work of Dr. Luis Martinez-Sobrido's lab is highlighted in Texas Monthly for advancing a universal flu vaccine - aimed at replacing annual shots with long-lasting immunity against all influenza...
Dr. Martinez-Sobrido's pioneering work toward developing a universal influenza vaccine was recently highlighted in the American Lung Association's email newsletter. His research aims to provide broad...
We are thrilled to announce that Dr. Ye has been selected to receive research funding from the American Lung Association. This award recognizes the innovation, strength, and impact of Dr. Ye's project...
